Disease activity is a major factor in menstrual disorders in systemic lupus erythematosus (SLE) patients not receiving alkylating therapy. However, the ovarian reserve of SLE women with normal menstruation is still unclear.
Methods:
Twenty-three SLE patients naïve to cytotoxic agents (SLE group) and nineteen SLE patients receiving current or previous cyclophosphamide (CTX) therapy (without other cytotoxic agents; SLE-CTX group) were enrolled. Twenty-one age-matched healthy women served as controls. All patients and controls had a regular menstrual cycle. Basal hormone levels, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and anti-Müllerian hormone (AMH), and antral follicle count (AFC) were analyzed in the two study groups and compared with the control group.
Results:
No significant differences were found between the SLE, SLE-CTX, and control groups in age, body mass index (BMI), and basal FSH and LH levels. The E2 (P=0.023) levels were high and the AMH (P=0.000) values and AFC (P=0.001) were significantly lower in the SLE and SLE-CTX groups compared to control. However, these values were similar between the SLE and SLE-CTX groups.
Conclusion:
SLE patients not receiving alkylating therapy who had normal menstruation and short illness duration still had an impaired ovarian reserve.
Get full access to this article
View all access options for this article.
References
1.
ShabanovaSS, AnanievaLP, AlekberovaZS, GuzovII. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol, 2008; 26:436–441.
2.
PasotoSG, MendonçaBB, BonfáE. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus, 2002; 11:175–180.
3.
FatnoonNN, AzarismanSM, ZainalD. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients. Singapore Med J, 2008; 49:413–418.
4.
Gonzalez-CrespoMR, Gomez-ReinoJJ, MerinoRet al.Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol, 1995; 34:737–741.
5.
van BeekR, van den Heuvel-EibrinkM, LavenJet al.Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab, 2007; 92:3869–3874.
6.
van RooijI, TonkelaarI, BroekmansFet al.Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause, 2004; 11:601–606.
7.
FanchinR, SchonauerL, RighiniC, GuibourdencheJ, FrydmanR, TaiebJ. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH, and LH on day 3. Hum Reprod, 2003; 18:323–327.
8.
SeiferD, MacLaughlinD, ChristianB, FengB, SheldenR. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002; 77:468–471.
9.
MuttukrishnaS, McGarrigleH, WakimR, KhadumI, RanieriD, SerhalP. Antral follicle count, anti-mullerian hormone and inhibin B: Predictors of ovarian response in assisted reproductive technology?Br J Obstet Gynecol, 2005; 112:1384–1390.
10.
FiciciogluC, KutluT, BaglamE, BakacakZ. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril, 2006; 85:592–596.
11.
AndersonR, ThemmenA, Al-QahtaniA, GroomeN, CameronD. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod, 2006; 21:2583–2592.
12.
KweeJ, EltingME, SchatsR, McDonnellJ, LambalkCB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol, 2007; 15:5–9.
13.
HaleGE, HughesCL, BurgerHG, RobertsonDM, FraserIS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause, 2009; 16:50–59.
14.
SaketosM, SharmaN, SantoroNF. Suppression of the hypothalamic-pituitary- ovarian axis in normal women by glucocorticoids. Biol Reprod, 1993; 49:1270–1276.
15.
GallantC, KennyP. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol, 1986; 14:161–177.
MignotMH, SchoemakerJ, KleingeldM, RaoBR, DrexhageHA. Premature ovarian failure. The association with autoimmunity. Eur J Obstet Reprod Biol, 1989; 30:59–65.
18.
Moncayo-NavedaH, MoncayoR, BenzR, WolfA, LauritzenC. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol, 1989; 160:1227–1229.
19.
WheatcroftNJ, SaltC, Milford-WardA, CookeID, WeetmanAP. Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod, 1997; 12:2617–2622.
20.
LubovskyJ, VisintinJ, BoyersS, AsariT, CaldwellB, deCheneyA. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab, 1990; 70:69–74.
21.
LubovskyJ, LlanesB, DaviesS, BinorZ, RadwanskaE, PongR. Ovarian autoimmunity: Greater frequency of autoantibodies in premature menopause and unexplained infertility than in general population. Clin Immunol, 1999; 90:368–374.
22.
ChernyshovVP, RadyshTV, GuraIV, TatarchukTP, KhominskayaZB. Immune disorders in women with premature ovarian failure in initial period. Am J Reprod Immunol, 2001; 46:220–225.
23.
RoeiyA, ValesiniG, FribergJet al.Autoantibodies and common idiotypes in men and women with sperm antibodies. Am J Obstet Gynecol, 1988; 158:596–603.
24.
LanirN, ZilbermanM, YronI, TennenbaumG, ShechterY, BrennerB. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. J Lab Clin Med, 1998; 131:548–556.
25.
MizutaniH, KurataY, KosugiSet al.Monoclonal anticardiolipin autoantibodies established from the (New Zealand white3BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum, 1995; 38:1382–1388.
26.
Delgado AlvesJ, KumarS, IsenbergDA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford), 2003; 42:893–899.
27.
AikawaNE, SallumAM, PereiraRMet al.Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol, 2012; 30:445–449.
28.
Al-MainiMH, MountzJD, Al-MohriHAet al.Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus, 2000; 9:132–139.
29.
LawrenzB, HenesJ, HenesMet al.Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus, 2011; 20:1193–1197.
